Novotech expands IT infrastructure in Asia-Pacific region with launch of Oracle trial service

asia pacific globe
Novotech adds Oracle’s Trial Management and Monitoring Cloud Service to support its work in the Asia-Pacific region. (blackred iStock)

Australia’s Novotech added to its IT infrastructure investment by launching Oracle’s Trial Management and Monitoring Cloud Service (TMMCS) to support its work in the Asia-Pacific region.

It is the largest implementation of TMMCS in that region, and Novotech becomes the first biotech-focused CRO in Asia-Pacific to use the technology.

TMMCS provides a real-time look into clinical trial progress and significant utilization rates of clinic and staff resources that helps lower costs while increasing speed and data quality, the company said. The technology also ensures regulatory compliance, integration with global studies and gives clinic staff and clients better data visibility.


Webinar: Optimizing Oncology Trials with a ctDNA Test Custom-Built for MRD and Molecular Monitoring

Join this webinar to discover the advantages of using Signatera™ (RUO), a novel assay custom-designed for each patient that detects circulating tumor DNA (ctDNA) with high sensitivity and specificity to monitor molecular residual disease, early recurrence, and treatment response across solid tumors.

“Oracle’s cloud technology provides a centralized trial database enabling improved access, control and governance of clinical data,” John Moller, M.D., Novotech’s chief executive, said in a statement. “The system is highly configurable allowing us to tailor process flows and alerts to client needs, as well as ensuring effective control on deviation.”

The CRO, which has seen a very busy year with the additions of new partners and clinics, now has 10 strategic collaborations with hospitals and research institutions across the Asia-Pacific region.

Suggested Articles

California data analytics company Saama Technologies has raised $40 million as it looks to bolster its artificial technology platform to “disrupt” clinical…

Thermo Fisher Scientific has moved to acquire viral vector developer and manufacturer Brammer Bio for $1.7 billion in cash.

French biotech AlzProtect has teamed up with CRO Parexel for its midstage test of AZP2006 in patients with progressive supranuclear palsy.